Results from the multinational, pivotal phase III SUNLIGHT* clinical trial of Lonsurf (trifluridine/tipiracil), alone or in combination with bevacizumab, in refractory metastatic colorectal cancer (mCRC) showed a statistically significant and clinically meaningful improvements in overall survival and progression-free survival for patients with refractory mCRC following disease progression or intolerance on two prior chemotherapy regimens compared to trifluridine/tipiracil alone.
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
